DXNVX Participates in the World's Largest Biopharmaceutical Conference 'CPHI Barcelona 2023'

DXVX announced on the 25th that it will participate in the world's largest biopharmaceutical conference, 'CPHI Barcelona 2023,' to enhance its recognition in the global market and actively seek overseas market partners.

CPHI, held this time in Barcelona, Spain, will host over 50,000 industry professionals, including more than 2,000 pharmaceutical companies, new drug development firms, and pharmaceutical suppliers.

Through this conference, DXVX plans to discuss various business collaborations such as discovering global partners for new drug development, supplying its products to overseas markets, distributing global items domestically, and licensing in/out to secure additional pipelines.

By setting up a booth at the venue, the company will accelerate partnership agreements with overseas partners focusing on its self-developed new drug pipelines, including anticancer vaccines, oral vaccines, anticancer antibody drugs, Evixgen ophthalmic disease pipelines, and upcoming microbiome-based biohealthcare products. In particular, it will introduce differentiated companion diagnostic technologies and services utilizing its top-tier genomic analysis expertise in Korea to negotiate joint development and service provision with global new drug development companies.

Additionally, it is currently discussing various cooperation plans to enhance the value of the anticancer vaccine pipeline developed by its affiliate Oxford Vacmedix (OVM). OVM published research papers on clinical results of the anticancer vaccine OVM-200 for non-small cell lung cancer (NSCLC), prostate cancer, ovarian cancer, and others in early October in the online journal Advanced Therapeutics.

Kwon Kyu-chan, CEO, who directly participated in CPHI World Wide, stated, “Through networking with global pharmaceutical and biopharmaceutical companies, we will significantly increase domestic and international sales and discover partners for joint development of new drugs and new products.” He added, “While expanding global partnerships through CPHI, we will build various cooperative networks for the development of pipelines such as antibody drugs currently under development and microbiome strains.”

Meanwhile, during the conference, DXVX plans to derive mutual cooperation plans through one-on-one meetings with numerous new drug developers and CRO and CMO companies, including global pharmaceutical companies such as Glenmark, the U.S. Abbvie, France’s Egis, and Italy’s SIIT.

This content was produced with the assistance of AI translation services.